Recent Trading Snapshot and Business Context
Embla Medical hf (CPSE:EMBLA) closed at DKK 27.65 on 7 October 2026, leaving the share down over the year but with mixed shorter term moves across the past week, month and past 3 months.
Recent action around Embla Medical hf has been choppy, with a 7-day share price return of 4.93% and a 90-day gain of 5.33%. This is set against a year-to-date share price decline of 13.59% and a 5-year total shareholder return down 36.44%, which points to short-term momentum rebuilding while long-term sentiment remains cautious.
Scan past Embla Medical hf and compare its recent swings with a curated group of 182 high quality undervalued stocks that also combine rebuilding momentum with established fundamentals.
Bulls point to Embla Medical hf's recent profit and revenue growth, as well as a discount to analyst targets, while bears focus on years of weak returns. Which case does the current valuation support next?
Most Popular Narrative: 17% Undervalued
On the most followed view, Embla Medical hf screens as undervalued, with a narrative fair value of DKK33.30 against the DKK27.65 last close. That gap is built on a set of specific growth and margin assumptions rather than vague optimism.
Recent product innovations, such as the NAVii bionics and NEURO HiTRONIC knee joint with a new U.S. reimbursement code, improve technological differentiation in high-growth, high-margin neuro-orthotics and prosthetics markets. This leverages accelerating adoption of advanced, connected medical devices and should help drive both top-line growth and long-term gross margin expansion.
See why 4 investors see Embla Medical hf as 17% undervalued .
That storyline is anchored on analysts expecting mid single digit to low double digit annual growth rather than aggressive breakneck expansion. Forecasts in the narrative assume revenue growth of about 8.4% a year, earnings growth of roughly 11.6% a year and a profit margin drifting toward 10.5%, all discounted at 7.22%.
The same framework implies a fair value of DKK33.30, which sits above both the last close and the DKK33.50 consensus analyst target embedded in the company data, even though the model uses a P/E of 20.9x that is lower than the cited 28.7x for the broader medical equipment peer group in the narrative. That combination of higher earnings base, modest multiple and a discount rate just above 7% is what drives the identified 17% undervaluation compared with Embla Medical hf's recent trading level.
Result: Fair Value of DKK33.30 (UNDERVALUED)
Still, the bullish Embla Medical hf story leans heavily on Prosthetics and Neuro Orthotics, while regulatory shifts and tariffs could pressure pricing power and profitability.
Find out about the key risks to this Embla Medical hf narrative .
Next Steps
With sentiment on Embla Medical hf split between caution and optimism, it helps to test the storyline against the raw numbers yourself and move quickly while this setup is still taking shape. To see which potential upsides analysts are watching most closely, review the 5 key rewards .
Looking For More Ideas Beyond Embla Medical hf?
Do not stop with Embla Medical hf when you can quickly scan fresh opportunities across income, quality and value using the Simply Wall Street Screener.
-
Target reliable cash payouts by checking companies that screen as steady income payers through the 224 dividend fortresses .
-
Hunt for quality at a discount by scanning the 182 high quality undervalued stocks that match strong fundamentals with prices below their estimated worth.
-
Focus on resilience first by filtering for 225 resilient stocks with low risk scores so you are not the last to spot sturdier portfolios when conditions change.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include EMBLA.CO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
